Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical Efficacy of Olaparib in IDH1/IDH2-Mutant Mesenchymal Sarcomas.
Eder JP, Doroshow DB, Do KT, Keedy VL, Sklar JS, Glazer P, Bindra R, Shapiro GI. Eder JP, et al. Among authors: sklar js. JCO Precis Oncol. 2021 Nov;5:466-472. doi: 10.1200/PO.20.00247. JCO Precis Oncol. 2021. PMID: 34994649 Free PMC article. Clinical Trial.
Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations).
Mahdi H, Hafez N, Doroshow D, Sohal D, Keedy V, Do KT, LoRusso P, Jürgensmeier J, Avedissian M, Sklar J, Glover C, Felicetti B, Dean E, Mortimer P, Shapiro GI, Eder JP. Mahdi H, et al. JCO Precis Oncol. 2021 Sep 7;5:PO.20.00439. doi: 10.1200/PO.20.00439. eCollection 2021. JCO Precis Oncol. 2021. PMID: 34527850 Free PMC article. Clinical Trial.
Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer.
Cecchini M, Zhang JY, Wei W, Sklar J, Lacy J, Zhong M, Kong Y, Zhao H, DiPalermo J, Devine L, Stein SM, Kortmansky J, Johung KL, Bindra RS, LoRusso P, Schalper KA. Cecchini M, et al. Cancer Res Commun. 2023 Jun 28;3(6):1132-1139. doi: 10.1158/2767-9764.CRC-23-0045. eCollection 2023 Jun. Cancer Res Commun. 2023. PMID: 37387791 Free PMC article.
Discovery of Gene Fusions in Driver-Negative Cancer Samples From the National Cancer Institute-Molecular Analysis for Therapy Choice Screening Cohort.
Kaluziak ST, Codd EM, Purohit R, Melli B, Kalyan P, Fordham JA, Kirkpatrick G, McShane LM, Chang TC, Yang G, Wang J, Williams PM, Karlovich C, Sklar J, Iafrate AJ. Kaluziak ST, et al. JCO Precis Oncol. 2024 Dec;8:e2400493. doi: 10.1200/PO-24-00493. Epub 2024 Dec 5. JCO Precis Oncol. 2024. PMID: 39637335 Free PMC article.
NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma.
Cecchini M, Cleary JM, Shyr Y, Chao J, Uboha N, Cho M, Shields A, Pant S, Goff L, Spencer K, Kim E, Stein S, Kortmansky JS, Canosa S, Sklar J, Swisher EM, Radke M, Ivy P, Boerner S, Durecki DE, Hsu CY, LoRusso P, Lacy J. Cecchini M, et al. Among authors: sklar j. Br J Cancer. 2024 Feb;130(3):476-482. doi: 10.1038/s41416-023-02534-1. Epub 2023 Dec 22. Br J Cancer. 2024. PMID: 38135713 Free PMC article. Clinical Trial.
Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH).
Flaherty KT, Gray RJ, Chen AP, Li S, McShane LM, Patton D, Hamilton SR, Williams PM, Iafrate AJ, Sklar J, Mitchell EP, Harris LN, Takebe N, Sims DJ, Coffey B, Fu T, Routbort M, Zwiebel JA, Rubinstein LV, Little RF, Arteaga CL, Comis R, Abrams JS, O'Dwyer PJ, Conley BA; NCI-MATCH team. Flaherty KT, et al. Among authors: sklar j. J Clin Oncol. 2020 Nov 20;38(33):3883-3894. doi: 10.1200/JCO.19.03010. Epub 2020 Oct 13. J Clin Oncol. 2020. PMID: 33048619 Free PMC article. Clinical Trial.
The NCI-MATCH trial: lessons for precision oncology.
O'Dwyer PJ, Gray RJ, Flaherty KT, Chen AP, Li S, Wang V, McShane LM, Patton DR, Tricoli JV, Williams PM, Iafrate AJ, Sklar J, Mitchell EP, Takebe N, Sims DJ, Coffey B, Fu T, Routbort M, Rubinstein LV, Little RF, Arteaga CL, Marinucci D, Hamilton SR, Conley BA, Harris LN, Doroshow JH. O'Dwyer PJ, et al. Nat Med. 2023 Jun;29(6):1349-1357. doi: 10.1038/s41591-023-02379-4. Epub 2023 Jun 15. Nat Med. 2023. PMID: 37322121 Free PMC article. Review.
The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design.
Flaherty KT, Gray R, Chen A, Li S, Patton D, Hamilton SR, Williams PM, Mitchell EP, Iafrate AJ, Sklar J, Harris LN, McShane LM, Rubinstein LV, Sims DJ, Routbort M, Coffey B, Fu T, Zwiebel JA, Little RF, Marinucci D, Catalano R, Magnan R, Kibbe W, Weil C, Tricoli JV, Alexander B, Kumar S, Schwartz GK, Meric-Bernstam F, Lih CJ, McCaskill-Stevens W, Caimi P, Takebe N, Datta V, Arteaga CL, Abrams JS, Comis R, O'Dwyer PJ, Conley BA; NCI-MATCH Team. Flaherty KT, et al. Among authors: sklar j. J Natl Cancer Inst. 2020 Oct 1;112(10):1021-1029. doi: 10.1093/jnci/djz245. J Natl Cancer Inst. 2020. PMID: 31922567 Free PMC article. Clinical Trial.
Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311.
Szatrowski TP, Dodge RK, Reynolds C, Westbrook CA, Frankel SR, Sklar J, Stewart CC, Hurd DD, Kolitz JE, Velez-Garcia E, Stone RM, Bloomfield CD, Schiffer CA, Larson RA. Szatrowski TP, et al. Cancer. 2003 Mar 15;97(6):1471-80. doi: 10.1002/cncr.11219. Cancer. 2003. PMID: 12627512 Free article. Clinical Trial.